Mobic Injection
Meloxicam
10mg/ml
Boehringer Ingelheim Pharma GmbH & Co. KG
| Pack size | 1.5ml Glass Ampoule x 5 |
|---|---|
| Dispensing mode | POM |
| Source | GERMANY |
| Agent | GULF DRUG EST. |
| Retail Price | 26.00 AED |
Available as:
Indications
Mobic Injection is used for:
Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis
Adult Dose
Oral
Rheumatoid arthritis; Ankylosing spondylitis
Adult: 15 mg daily as a single dose. Patients w/ increased risk of adverse effects: Initially, 7.5 mg daily.
Acute exacerbations of osteoarthritis
Adult: 7.5 mg daily up to max 15 mg daily as a single dose.
Elderly: 7.5 mg daily for long-term treatment.
Child Dose
Oral
Juvenile rheumatoid arthritis
Child: >2 yr 0.125 mg/kg once daily. Max: 7.5 mg daily.
Renal Dose
Renal impairment: Mild to moderate: No dosage adjustment needed.
Severe: Not recommended.
Dialysis patient: 7.5 mg daily.
Administration
May be taken with or without food. May be taken w/ meals if GI discomfort occurs.
Contra Indications
Hypersensitivity to meloxicam, aspirin or other NSAIDs; severe hepatic impairment; bleeding disorders; renal failure without dialysis. Rectal admin in patients with proctitis, haemorrhoids or rectal bleeding.
Precautions
History of GI disease, asthma, hypertension, CVD or risk factors, fluid retention or heart failure. Monitor patients with advanced renal disease. May impair ability to drive or operate machinery. Elderly. Pregnancy (avoid in the 3rd trimester) and lactation.
Pregnancy-Lactation
Pregnancy category: C; D in third trimester of pregnancy; drug should be avoided in late pregnancy
Lactation: Unknown whether drug is excreted in breast milk; effect on infant unknown; not recommended
Interactions
Increased risk of severe GI effects w/ aspirin or warfarin. May antagonise antihypertensive effects of ACE inhibitors and angiotensin II receptor antagonists. May reduce natriuretic effects of furosemide and thiazides. Enhanced toxicity of methotrexate. May increase plasma lithium concentration.
Adverse Effects
Side effects of Meloxicam :
1-10%
Indigestion (3.8-9.5%), Upper respiratory infection (<8.3%), Headache (2.4-8.3%), Diarrhea (1.9-7.8%), Nausea (2.4-7.2%), Abdominal pain (1.9-4.7%), Edema (0.6-4.5%), Anemia (<4.1%), Dizziness (1.1-3.8%), Constipation (0.8-2.6%), Angina (<2%), Congestive heart failure (<2%), Decreased platelet aggregation, purpuric disorder (<2%), Gastrointestinal (GI) hemorrhage (<2%), GI perforation, GI ulcer (<2%), Hepatitis (<2%), Hypertension (<2%), Inflammatory disorder of digestive tract (<2%), Myocardial infarction (<2%), Vomiting (<3%)
<1%
Anaphylactoid reaction, Angioedema, Fever, Asthma, bronchospasm, Cerebrovascular accident, Erythema multiforme, erythroderma, Immune hypersensitivity reaction, Interstitial nephritis, renal failure, Jaundice, liver failure, Stevens-Johnson syndrome, Tinnitus, hearing loss, Toxic epidermal necrolysis
Potentially Fatal: Stevens Johnson syndrome, thrombocytopenia, interstitial nephritis and idiosyncratic liver abnormality.
Mechanism of Action
Meloxicam is an oxicam derivative which exhibits analgesic, antipyretic and anti-inflammatory actions. It reversibly inhibits the cyclooxygenase-1 and -2 (COX-1 and -2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors.
Note
Mobic 10mg/ml Injection manufactured by Boehringer Ingelheim Pharma GmbH & Co. KG. Its generic name is Meloxicam. Mobic is availble in United Arab Emirates.
Farmaco UAE drug index information on Mobic Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.